Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- Duvyzat (givinostat)
- everolimus
Interactions between your drugs
everolimus givinostat
Applies to: everolimus, Duvyzat (givinostat)
MONITOR: Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the blood concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus.
MANAGEMENT: The possibility of prolonged and/or increased pharmacologic effects of everolimus therapy should be considered during coadministration with CYP450 3A4 and/or P-glycoprotein inhibitors, including adverse effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.
References (2)
- (2009) "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals
- (2021) "Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc
Drug and food interactions
everolimus food
Applies to: everolimus
GENERALLY AVOID: Grapefruit juice may significantly increase the plasma concentrations of orally administered everolimus. The mechanism is inhibition of CYP450 3A4 and P-glycoprotein activity in the gut wall by certain compounds present in grapefruit.
MANAGEMENT: Patients treated with everolimus should avoid consumption of grapefruit and grapefruit juice.
References (1)
- (2009) "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals
givinostat food
Applies to: Duvyzat (givinostat)
ADJUST DOSING INTERVAL: Food increases the systemic exposure of givinostat. An open-label, randomized, crossover, single dose food effect study conducted in 12 healthy males used givinostat liquid filled capsules. Subjects received a single oral dose of givinostat (100 mg) in the fasting state or after a high-fat standard meal, with a washout period of at least 1 week in between. The high-fat standard meal resulted in an increase in systemic exposure (AUC) and maximum plasma concentration (Cmax) of about 40% and 23%, respectively, when compared to the fasted state. Additionally, the time to maximum concentration (Tmax) was delayed slightly from 2 to 3 hours.
MANAGEMENT: Givinostat should be administered with food to increase its absorption. In the case of the oral suspension, this can also help mask its bitter taste.
References (2)
- (2024) "Product Information. Duvyzat (givinostat)." ITF Therapeutics, LLC
- Italfarmaco Spa (2024) Center for drug evaluation and research. Application number: 217865Orig1s000. Integrated review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217865Orig1s000IntegratedR.pdf
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Agamree
Agamree (vamorolone) is an FDA-approved treatment for Duchenne muscular dystrophy (DMD) to improve ...
Emflaza
Emflaza (deflazacort) is a corticosteroid medication used to treat a rare genetic disorder called ...
Viltepso
Viltepso (viltolarsen) is used for the treatment of Duchenne muscular dystrophy (DMD) treatable ...
Elevidys
Elevidys is a gene therapy for Duchenne muscular dystrophy, that is given as a one-time infusion ...
Amondys 45
Amondys 45 (casimersen) is used to treat Duchenne muscular dystrophy (DMD) with a genetic mutation ...
Vyondys 53
Vyondys 53 is used for Duchenne muscular dystrophy (DMD) in children and young adults with a ...
Exondys 51
Exondys 51 is used for Duchenne Muscular Dystrophy (DMD) in children and young adults with a ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.